Latest News

(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), adjuvant treatment with BCG is guideline-recommended on the basis of proven benefits in disease recurrence. While BCG is efficacious, many patients eventually develop BCG-unresponsive disease. For many years, […]

(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), adjuvant treatment with BCG is guideline-recommended on the basis of proven benefits in disease recurrence. While BCG is efficacious, many patients eventually develop BCG-unresponsive disease. Despite guideline-concordant care, […]

(UroToday.com) In this study by Evan Gross and colleagues, the authors explore the survival outcomes of patients with metastatic renal cell carcinoma (mRCC) who received Immune Checkpoint Inhibitor Therapy (ICI) with or without cytoreductive nephrectomy (CN). With the role of CN increasingly being re-evaluated, especially in the context of CARMENA and SURTIME, the authors specifically wanted […]

(UroToday.com) The American Urologic Association annual meeting included a State-of-the-Art Lecture by Dr. Brian Chapin who discussed personalized medicine in the management of prostate cancer across the patient care continuum. Dr. Chapin notes that the way we think about the personalized approach to prostate cancer therapy involves seeing a patient in the clinic and assessing them on […]

(UroToday.com) In this rapid review for the American Urologic Association (AUA) plenary session, Dr. Cora Sternberg summarized the current status of first and second-line therapy for advanced and metastatic urothelial cancer – while also touching on changes that are upcoming.

(UroToday.com) The bladder cancer non-invasive session at the 2021 American Urologic Association (AUA) annual meeting included a presentation by Dr. Vidit Sharma discussing adverse events after transurethral resection of intermediate-risk non-muscle-invasive bladder cancer (NMIBC). Transurethral resection of bladder tumor (TURBT) is a common urologic procedure with a reported 30-day complication rate of about 6% according to […]

(UroToday.com) In this presentation, Dr. Chris Bagma, Professor of Urology at Erasmus MC, focused on anxiety and quality-of-life for men on active surveillance for prostate cancer.

(UroToday.com) At the 2021 American Urologic Association (AUA) annual meeting, the bladder cancer non-invasive session included a presentation by Dr. Sandeep Gurram discussing interim results of a phase 1 trial combining durvalumab and Vicineum in patients with high-grade non-muscle invasive bladder cancer (NMIBC) previously treated with bacillus calmette–guérin (BCG) intravesical therapy. Indeed, radical cystectomy is the […]

(UroToday.com) The bladder cancer non-invasive session at the American Urological Association, (AUA) included a presentation by Dr. Anirban Mitra discussing the impact of anti-adenoviral antibody levels for predicting nadofaragene firadenovec response in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Nadofaragene firadenovec is a recombinant adenoviral vector-based intravesical therapeutic that delivers a copy of human IFNa2b gene to […]

(UroToday.com) In this presented study by Dr. Kristian Stensland takes a deeper dive into the TOAD trial specifically assessing whether prior androgen deprivation therapy (ADT) use impacted the efficacy of ADT timing after PSA relapse in men with PSA-relapsed and non-curable prostate cancer.